Editor @TheBullished. Ex-Forbes reporter/editor, UNC Chapel Hill, Columbia MBA. Bringing smart coverage and analysis to every corner of the stock market.
SEC Filings
The CIRM grant funds RECLAIM-LN, a potentially registrational trial of FT819 off-the-shelf CAR T-cell therapy in roughly 53 patients.
SEC Filings
Both drugs hit their primary goals in a pivotal late-stage wet AMD trial, clearing the way for a multi-indication FDA application before year-end.
SEC Filings
A contested board election at Anavex's annual meeting triggered a change-in-control clause, immediately vesting all outstanding unvested equity grants.
SEC Filings
The clinical-stage biotech expects initial safety and efficacy data from the open-label DMD study in the first half of 2027.
SEC Filings
The FDA approved Atebrioz on Friday; the same day, Mirum's late-stage AZURE-1 hepatitis delta study met its primary endpoint at week 24.
SEC Filings
The fixed-price agreement obligates $22.3 million upfront, with the remainder tied to milestone completions and future congressional appropriations.
SEC Filings
An investor presentation filed Monday shows INBRX-106 combined with pembrolizumab achieved an 80% confirmed response rate versus 33% for the checkpoint inhibitor alone.
SEC Filings
Four-year data on AMT-130 fell well short of the 80% slowing reported in the updated three-year analysis, complicating a biologics license application already before the FDA.
SEC Filings
Keros plans to pass 25% of the net proceeds to stockholders after the milestone triggers under its Takeda license agreement.
SEC Filings
The biotech lifted its 2026 outlook to $410–$420 million, implying nearly 60% annual revenue growth, in a Tuesday 8-K filing.
SEC Filings
The biologics license application covers moderate-to-severe hidradenitis suppurativa in adults and adolescents as young as 12.
SEC Filings
Z-basivarsen cut hand-opening time by 3.2 seconds at six months and diverged from a natural history control group at 12 months across four measures.